EYLEA HD^® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

Regeneron Pharmaceuticals, Inc. announced that the US FDA has approved EYLEA HD^® Injection 8 mg for the treatment of patients with macular edema following RVO with up to every 8-week dosing after an initial monthly dosing period.